267 completed, 80 terminated, 33 active not recruiting, 29 unknown. 454 Phase 2, 77 Phase 1, 14 Phase 3.
Follow Gemzar: new trials by email Literature Review of Gemzar trials Research Report on Gemzar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-11-01 | 2026-11-04 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms Ablation Therapy, Biospecimen Collection, Computed Tomography - Pancreatic Cystic Neoplasm | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2026-05-12 | 2026-05-29 |
| Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Cemiplimab Plus Gemcitabine - Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 2 | Recruiting | University of California, San Diego | 43 | 2026-05-06 | 2026-06-08 |
| ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 61 | 2026-03-25 | 2026-05-19 |
| A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients Ascorbate, Gemcitabine, radiation therapy - Pancreatic Neoplasm | Phase 2 | Withdrawn | Joseph J. Cullen, MD, FACS | 2025-12-31 | 2025-03-10 | |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-11-09 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer N-803 and BCG, N-803 and Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2025-11-01 | 2025-10-16 |
| Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer sintilimab, nab-paclitaxel, gemcitabine - Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 50 | 2025-03-20 | 2025-01-22 |
| Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, TheraBionic P1 - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-02-28 | 2026-08-10 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer Gemcitabine, N-803, M-CENK - Platinum-resistant Ovarian Cancer | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2024-11-06 | 2026-07-01 |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer Organoid-guided treatment, Taxane, Capecitabine - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 252 | 2024-10-01 | 2024-11-25 |
| AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC AGEN1423, Botensilimab, Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Active not recruiting | Bruno Bockorny | 24 | 2024-08-08 | 2026-07-09 |
| A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Nab paclitaxel, Gemcitabine, NovoTTF-200T(P) - Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer | Phase 2 | Recruiting | Ashish Manne | 38 | 2024-07-01 | 2026-04-08 |
| A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma CEND-1, Gemcitabine, Nab paclitaxel - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 120 | 2024-03-19 | 2024-09-04 |
| Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial Cisplatin, Gemcitabine Hydrochloride, Infigratinib Phosphate - Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 2 | Withdrawn | Emory University | 2024-03-01 | 2023-12-26 | |
| Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 30 | 2024-02-13 | 2026-04-22 |
Showing 20 of 454. Sign in to see all of them.
Pancreatic Neoplasms (155) · Carcinoma, Non-Small-Cell Lung (41) · Breast Neoplasms (38) · Neoplasm Metastasis (31) · Neoplasms (30) · Lung Neoplasms (25) · Urinary Bladder Neoplasms (24) · Ovarian Neoplasms (20) · Cholangiocarcinoma (17) · Hodgkin Disease (15) · Sarcoma (15) · Gallbladder Neoplasms (14) · Recurrence (14) · Lymphoma (12) · Adenocarcinoma (10)
National Cancer Institute (NCI) (43) · M.D. Anderson Cancer Center (28) · Eli Lilly and Company (24) · SCRI Development Innovations, LLC (11) · Columbia University (8) · SWOG Cancer Research Network (8) · Washington University School of Medicine (8) · Stanford University (7) · ECOG-ACRIN Cancer Research Group (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · Hellenic Oncology Research Group (6) · Mayo Clinic (6) · IRCCS San Raffaele (5) · Massachusetts General Hospital (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5)
United States (321) · China (29) · Spain (28) · Canada (25) · Italy (23) · Germany (22) · France (19) · United Kingdom (18) · Belgium (14) · Greece (11) · South Korea (11) · Australia (10) · Poland (9) · Netherlands (7) · Russia (7)
Yago Nieto, MD, PHD (6) · Michele Reni, MD (5) · Hedy Kindler (4) · Vassilis Georgoulias, MD (4) · David R. Spigel, MD (3) · Denise A. Yardley, MD (3) · Dung Le, MD (3) · Robert L Fine, MD (3) · Albert Koong (2) · Armando Santoro, MD (2) · Benjamin Tan, M.D. (2) · Gerold Bepler, MD, PhD (2) · Herbert Zeh, MD (2)
PMID 31401903, PMID 29929491, PMID 15297403, PMID 16277889, PMID 18650621, PMID 19087987, PMID 19224841, PMID 19636002, PMID 19661042, PMID 19819914, PMID 19932054, PMID 20163987, PMID 20421819, PMID 20439197, PMID 20497920, PMID 20585851, PMID 20662793, PMID 20863157, PMID 20881641, PMID 20981545, PMID 21120580, PMID 21135251, PMID 21833720, PMID 22094934, PMID 22218909, PMID 22634531, PMID 22736441, PMID 23444220, PMID 23458624, PMID 23475103, PMID 23720019, PMID 23782814, PMID 23897705, PMID 24327518, PMID 24687408, PMID 24802654, PMID 24824628, PMID 25091263, PMID 25278454, PMID 25459391, PMID 25492104, PMID 25538178, PMID 25662596, PMID 25794066, PMID 25837499, PMID 25964250, PMID 25981169, PMID 26067687, PMID 26119093, PMID 26199392
U10CA180820 (10), U10CA032102 (7), U10CA021115 (5), N01CM00038 (4), N01CM62204 (4), U10CA021661 (4), N01CM00071 (3), N01CM17102 (3), N01CM62201 (3), P30CA014599 (3), P30CA036727 (3), U10CA027469 (3), U10CA180868 (3), U10CA180888 (3), 2015 (2)